RankingsLogo

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Alnylam is a biopharmaceutical company focused on discovering and developing RNA interference therapeutics to treat genetic illnesses.

Ticker: ALNY

Humankind Value: $26.5 B

Revenue: $689.5 M

Market Cap: $19.6 B

Badge100_2024
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Alnylam Pharmaceuticals, Inc., though not profitable, operates in a manner that is a net positive for humanity, primarily due to Healthcare R&D ($24.7 B), Pharmaceuticals ($2.0 B), and Medical Services ($41.8 M). Positive value from Healthcare R&D, Pharmaceuticals, and Medical Services is linked to an estimate of 510,000 additional years lived by people worldwide. The Humankind Value of this company can improve with reductions in Greenhouse Gases (-$44.5 M) and Air Pollution (-$5.6 M). Healthcare R&D, Pharmaceuticals, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities. Medical Services is largely a consequence of the actions of supply chain partners.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings